Intellia Therapeutics, Inc. (NTLA) — SEC Financial Statements & Analysis

Intellia Therapeutics, Inc. (NTLA) is a in vitro & in vivo diagnostic substances company, incorporated in DE. Intellia Therapeutics, Inc. trades on Nasdaq as: NTLA. Intellia Therapeutics, Inc. (NTLA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Intellia Therapeutics, Inc. carries a market cap of $2.26B, a P/E ratio of -5.65x, a P/B ratio of 3.10x, a P/S ratio of 37.95x, an enterprise value of $2.15B, and an EV/EBITDA multiple of -5.19x. On profitability, it posts an operating margin of -711.66%, a net margin of -672.16%, a Return on Equity (ROE) of -6424.79%, a Return on Assets (ROA) of -45.55%, and a Return on Invested Capital (ROIC) of -73.71%. Per share, it reports EPS of $-3.00, diluted EPS of $-3.00, free cash flow per share of $-2.61, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 12.58% year-over-year, net income growth of -16.71% year-over-year, and EPS growth of -35.27% year-over-year. On the balance sheet, it maintains a current ratio of 6.65x, a quick ratio of 5.61x, working capital of $448.44M, a debt-to-equity ratio of 0.18x, a debt ratio of 0.15, free cash flow of $-348.69M (TTM), and net debt of $-106.13M. Figures sourced from SEC EDGAR.

Market Cap

$2.26B

P/E TTM

-5.65x

EPS TTM

$-3.00

P/B TTM

3.10x

ROE TTM

-6424.79%

ROA TTM

-45.55%

Debt To Equity

0.18x

Free Cash Flow TTM

$-348.69M

Net Revenue TTM Growth 1Y

12.58%

Data as of 2026-06-30 · Source: SEC EDGAR